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Summary
Costimulatory molecules are important regulators of
T cell activation and thus favored targets for thera-
peutic manipulation of immune responses. One of the
key costimulatory receptors is CD80, which binds the
T cell ligands, CD28, and CTLA-4. We describe a set
of small compounds that bind with high specificity
and low nanomolar affinity to CD80. The compounds
have relatively slow off-rates and block both CD28
and CTLA-4 binding, implying that they occlude the
shared ligand binding site. The compounds inhibit pro-
inflammatory cytokine release in T cell assays with sub-
micromolar potency, and as such, they represent prom-
ising leads for the development of novel therapeutics
for immune-mediated inflammatory disease. Our re-
sults also suggest that other predominantly  proteins,
such as those that dominate the cell surface, may also
be accessible as potentially therapeutic targets.
Introduction
Optimal activation of T cells requires the interaction of
the T cell receptor (TcR) with major-histocompatibility
complex (MHC)-peptide antigens and the engagement
of a costimulatory receptor by its respective ligand. The
most important and well-characterized T cell costimu-
latory ligands are CD28 and CTLA-4 (CD152), which en-
gage CD80 and CD86 receptors on antigen-presenting
cells (APCs). Ligation of CD28 enhances T cell activation
[1, 2], resulting in enhanced stability of cytokine mRNA
[3], increased glucose metabolism [4], and upregulation
of antiapoptotic genes [5]. In contrast, engagement of
CTLA-4 delivers a negative signal to the T cell, resulting
in attenuation of kinase activation [6] and overall inhibi-
tion of activation [7]. T cell costimulation is regulated
by altered expression profiles of both costimulatory re-
ceptors and their ligands over the course of the im-
mune response. For example, CD28 is constitutively ex-
pressed on naive cells, whereas CTLA-4 expression is
upregulated on activated T cells [8]. Similarly, while CD86
is constitutively expressed on monocytes, B cells, and*Correspondence: brendan.classon@avidex.com
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59 Bartholomew Close, London, EC1A 7BE, United Kingdom.dendritic cells, CD80 is only expressed at significant
levels on these cells following activation [9–14]. There-
fore, it is generally believed that CD86 is the major cos-
timulatory receptor in primary immune responses,
whereas CD80 is thought to act as the dominant costi-
mulatory receptor in established immune responses
[15]. Although CD28 and CTLA-4 are each capable of
binding both CD80 and CD86, there are data that sug-
gest CD80 is the preferred receptor for CTLA-4 [16, 17].
The net inhibitory effect of this interaction is thought
to play a role in maintaining immune tolerance [18], a
possibility consistent with the observation that anti-
CTLA-4 blocking antibodies enhance antitumor T cell
responses in vivo [19]. Conversely, the elevated expres-
sion of CD80 on activated APCs and activated T cells
[20] suggests a role for CD80 in ongoing immune re-
sponses, particularly at distal sites of inflammation in
autoimmune disease [21, 22].
An important consequence of targeting T cell costim-
ulation as a means of immunosuppression is that only
those cells that have already received an antigen-spe-
cific signal via their TcR are expected to be susceptible
to inhibition [15]. Some degree of antigen-specific inhi-
bition is therefore anticipated, which may enhance the
therapeutic potential of costimulation blockade. The ef-
fectiveness of costimulatory blockade as a means of
immunosuppression was first demonstrated over a de-
cade ago, when it was shown that CTLA-4Ig inhibits
graft rejection [23] and induces long-term tolerance in
mice [24]. Subsequently, CTLA-4Ig has been shown to
be an effective antagonist of costimulation in rodent mod-
els of autoimmune disease, including collagen-induced
arthritis [25, 26] and the experimental allergic encepha-
lomyelitis (EAE) model of multiple sclerosis (MS) [27,
28]. CTLA-4Ig is thought to block CD28 signaling by
preventing its engagement by CD80 and CD86, al-
though a direct immunomodulatory effect of CTLA-4Ig
on dendritic cells has recently been proposed [29]. Se-
lective blockade of CD80 with monoclonal antibodies
(mAbs) in the mouse EAE model has also resulted in
decreased severity of disease [30–33]. For example,
blocking CD80 with monoclonal antibodies during the
initiation phase of EAE decreased severity of disease
[30, 31]. Furthermore, it was shown that the selective
blockade of costimulation using anti-CD80 F(ab) frag-
ments during EAE remission could prevent antigenic
epitope spreading and disease relapse [32, 33]. How-
ever, since CD80 is capable of engaging both stimula-
tory (CD28) and inhibitory (CD152) ligands [16], it is
likely that timing and duration of CD80 blockade in the
clinical setting will be important in achieving the de-
sired therapeutic outcome.
Encouraging results in animal models have led to
clinical trials with CTLA-4Ig in rheumatoid arthritis [34],
and a recent phase III trial has since confirmed this
promise [35]. A significant drawback of protein-based
therapies, however, is their high treatment cost and the
requirement for parenteral administration. By compari-
son, small compound inhibitors offer an attractive alter-
native, provided that target specificity, potency, and
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to identify small compound inhibitors of the CD80/CD28
interaction have been reported. In the first of these, a mi-
crobial metabolite isolated from a natural product li-
brary was shown to inhibit the CD28/CD80 interaction
with an IC50 of 0.3 M in a biochemical assay, but a
relatively high concentration of the compound (20 M)
was required to inhibit IL-2 production in a cellular as-
say [36]. In a second study, a series of condensed aro-
matic peptide inhibitors with increased cellular activity
were identified [37, 38]; however, nonspecific binding
of these compounds to other proteins [39] suggested
that they were poor lead candidates. Another study
identified a third class of compounds that inhibit the
CD80/CD28 interaction, but their lack of potency in cel-
lular adhesion assays and their relatively weak inhibi-
tion of the intracellular CD28/PI3-kinase interaction
were disappointing [40, 41].
We report herein a series of small compounds
(average MW 424 ± 75) that bind specifically to human
CD80 with low nanomolar affinity in standard binding
assays. The compounds antagonize CD28 and CTLA-4
binding to CD80 and inhibit the release of the proin-
flammatory cytokines IL-2, IFNγ, and TNFα at sub-
micromolar doses in T cell costimulation assays. Our
data suggest that these agents represent promising
leads for the development of novel small molecule au-
toimmune therapies.
F
I
Results
Identification and Synthesis of Small a
nMolecule Inhibitors
Our interest in CD80 inhibitors was prompted by Active- p
hBiotech AB, who identified novel small compounds [42]
that blocked the CD28/CD80 interaction in a scintilla- t
ftion proximity assay [43]. The inhibitory properties of
selected compounds were confirmed at Avidex Ltd. in o
ca CD80/CD28 time-resolved fluorescence resonance en-
ergy transfer (TR-FRET) assay (see Experimental Pro- t
wcedures), which was also used to screen compound
analogs produced in lead optimization programs. The t
Estructures of a lead pyrazoloquinoline (compound 1)
and a more potent analog (compound 2) together with C
lfour representative examples of a second (pyrazolocin-
noline) series of compounds (compounds 3–6) are C
tshown in Figure 1. The degree to which each com-
pound inhibited the CD80/CD28 interaction in the TR- E
tFRET assay was determined and expressed as an EC50
value. The data presented in Table 1 show that we were 4/CD80 interaction compared to CD28/CD80 [16].
Table 1. Biochemical and Cellular Inhibitory Properties of CD80 Compounds
SPRTR-FRET Jurkat Cell
Compound EC50 (nM) KD (nM) kd (s−1) ka (M−1s−1) IC50 (M)
1 630 125 0.12 988,400 ND
2 66 11.3 0.023 2,237,250 13.5 (n = 2)
3 4.7 5.0 0.0089 1,708,000 1.6 ± 0.77 (n = 3)
4 3.0 3.1 0.0036 1,146,000 0.84 ± 0.19 (n = 4)
5 1.3 1.3 0.0024 1,873,000 0.77 ± 0.33 (n = 3)
6 2.7 2.4 0.0025 1,053,000 0.75 ± 0.14 (n = 3)ND, not determined.igure 1. Chemical Structures of the Small Molecule Human CD80
nhibitorsble to identify inhibitors with potency as low as 1.3
M. Inhibition surface plasmon resonance (SPR) ex-
eriments were also undertaken to confirm the early
its identified by TR-FRET. In the SPR experiments, bio-
inylated CD80 was immobilized onto the sensor sur-
ace, and a series of samples containing a fixed amount
f CD28-Fc and an increasing concentration of lead
ompound were injected over the surface. A concentra-
ion-dependent inhibition of CD28-Fc binding to CD80
as observed for each compound and two representa-
ive examples (compounds 2 and 5; Figure 2A). The
C50 values of compounds 2 and 5 for inhibition of
D28/CD80 binding in SPR (see Figure 2 legend) corre-
ated well with those determined by TR-FRET (Table 1).
ompounds 2 and 5 also inhibited CTLA-4-Fc binding
o CD80 (Figure 2B), but with 3-fold and 1.7-fold higher
C50 values, respectively (see Figure 2 legend), consis-
ent with the higher affinity and bivalency of the CTLA-
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1653Figure 2. Inhibition of the CD28/CD80 Binding on the Biacore
Soluble biotinylated CD80 protein was immobilized on a streptavi-
din-conjugated CM5 chip prepared using amine coupling chemis-
try. Soluble-CD28-Fc (A) or CTLA-4Fc (B) at 270 nM and 5.9 pM,
respectively, were mixed with increasing doses of compound 2 or
compound 5 and injected onto the immobilized sCD80 surface. All
compound dilution series were 3-fold dilutions (6 points) from 1000
µM, except inhibition of the CD28-CD80 interaction by compound
5 ([B], right panel), where 5-fold dilutions (6 points) from 100 µM
were used. The EC50 values were calculated as follows: for CD28-
CD80 inhibition by compound 2, 45 nM, and compound 5, 3 nM;
and for CTLA4-CD80 inhibition by compound 2, 142 nM, and com-
pound 5, 5 nM.Small Molecule Inhibitors Are Uniquely
Specific for Human CD80
The properties of the compounds were further investi-
gated by direct SPR binding experiments, which also
enabled precise identification of target protein as CD80.
Selected fusion proteins were immobilized on a streptavi-
din-coated sensor surface, and titrated amounts of com-
pound were applied to the surface. The data of Figure
3 show that compound 2 binds specifically to human
CD80 but not the related protein, human CD86 (Figure assays [44]. In all experiments, IL-2 secretion by Jurkat
Figure 3. Binding of Compound 2 to Human
CD80
Biotinylated human CD80 (A) and CD86 (B)
were labeled on to spot 1 and spot 2,
respectively, of a CM5 chip which had been
prepared with streptavidin using standard
amine coupling chemistry. The two proteins
were bound to the chip to approximately
3000 RU. A range of compound concentra-
tions (1000 nM and six 3-fold dilutions
thereof) were injected sequentially, with
solvent correction performed using a stan-
dard series of DMSO concentrations. A 200
s injection was used, followed by a dissoci-
ation phase of 400 s. The solid black line
overlayed on each sensorgram trace repre-Figure 4. Binding of Compound 4 and CD28-Fc to Immobilized
CD80 Analyzed by SPR
Compound and protein binding (normalized as a percentage of
maximum binding for ease of comparison) is shown over time. The
dissociation phase of the curve reveals rapid dissociation of the
natural ligand (CD28; kd, R 1.6 s−1 [54]) compared to the small
compound.3B), nor human CD28-Fc (data not shown), nor do the
compounds bind mouse, rat, or canine CD80, although
binding to rhesus monkey CD80 was observed (data
not shown). The binding affinity and kinetic rate con-
stants for a selection of CD80 compounds are summa-
rized in Table 1. Significantly, all the inhibitors exhibit
significantly slower off-rates than the natural ligand
(CD28), and a representative example (compound 4) is
shown in the SPR sensorgram depicted in Figure 4.
CD80-Specific Small Molecules Block T Cell
Costimulation in Cell-Based Assays
The activity of the CD80-specific compounds in T cell
costimulation assays was investigated. Since CD80
and CD86 are coexpressed on Raji cells (Figure 5A, in-
set), their relative contributions to costimulation-depen-
dent IL-2 release were investigated in blocking experi-
ments (Figure 5A). Partial inhibition of IL-2 secretion
(approximately 25%) was observed in the presence of
an anti-CD86 mAb (Figure 5A, shaded bars), whereas
a CD80 mAb resulted in more pronounced inhibition,
reaching a plateau of 95% at a mAb concentration of
0.03 g/ml (Figure 5A, solid bars). This result was con-
sistent with a previous report showing functional domi-
nance of CD80 over CD86 on Raji cells in proliferationsents a global fit assuming a 1:1 interaction
between the compound and protein.
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Costimulation Assay
(A) Jurkat T cells were stimulated with anti-
CD3 mAb in the presence of Raji B cells,
which coexpress CD80 and CD86 (inset).
Anti-CD80 mAb (solid bars) or anti-CD86
mAb (shaded bars) or both mAbs (open bars)
were added to the cultures at various con-
centrations. IL-2 release is expressed as a
percentage of maximum release obtained in
the absence of blocking mAbs. “No-costim”
control indicates the level of IL-2 secreted by
Jurkat T cells and CD3mAb in the absence of
Raji cells.
(B) CD80-specific small compounds 3–6 in-
hibit Jurkat T cell costimulation. Inhibition of
IL-2 release by compounds (shaded bars) in
the Jurkat assay (A) is expressed as percen-
tage of maximum release obtained in the
presence of DMSO alone. Compounds failed
to inhibit the anti-CD3/anti-CD28 mAb (CD80-
independent) control assay (open bars).cells was insignificant in the absence of added Raji T
0cells (see Figure 5A, “no costim” control). Using this
assay, dose-dependent inhibition of IL-2 release was t
iseen for all four compounds (Figure 5B), with IC50 val-
ues ranging from 0.75–0.84 M (Table 1). An earlier lead p
ccompound (compound 2) with a lower biochemical
EC50 (66 nM) exhibited significantly lower potency (13.5
M) in the cell assay than lead optimized compounds D
3–6. None of the compounds showed significant inhibi-
tion of IL-2 release in the control assay, when anti-CD28 T
santibody was added to overcome the effect of com-
pound-mediated CD80 blockade (Figure 5B, open bars). m
lFinally, compounds were tested in assays using puri-
fied peripheral blood CD4+ primary T cells in place of p
aJurkat cells. CD3 mAb and Raji cells were used to pro-
vide the primary stimulus and costimulation as before, i
sand supernatants were assayed for IL-2, TNFα, and
IFNγ at 24 and 48 hr. The data of Figure 6A show that p
ecompound 6 inhibited IL-2 secretion in the CD4+ T cell
assay with approximately similar potency to that ob- C
Tserved with the Jurkat cell assay (IC50 = 0.75 M versus
0.57 M). In the same assay, compound 6 also inhibited aNFα and IFNγ secretion with IC50 values of 0.97 M and
.15 M, respectively. For IL-2 and IFNγ, compound po-
ency was reduced approximately 2-fold when compar-
ng the 24 hr and 48 hr time points, whereas compound
otency with respect to TNFα inhibition was un-
hanged over this time period (Figure 6D).
iscussion
here is a strong biological rationale for developing
mall molecule CD80 antagonists. The challenge facing
edicinal chemists hoping to exploit this opportunity
ies in the difficulties of identifying inhibitors of protein-
rotein interactions [45–47]. A low success rate is usu-
lly ascribed to the fact that small orally bioavailable
nhibitors bind with low affinity to the (generally) flat
urfaces found at the interface between interacting
roteins. The compounds reported herein appear to be
xceptions to this rule, given that they inhibit the CD80/
D28 interaction with IC50 values as low as 1–3 nM.
he binding site on CD80 for CTLA-4 (and presumably
lso CD28) is a shallow depression that comprises
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Purified T cells were incubated with anti-CD3 mAb and Raji cells in the presence of titrated amounts of compound 6. After 24 and 48 hr (data
not shown), supernatants were assayed for IL-2, IFNγ, and TNFα (A–C). Cellular IC50 values calculated with ExcelFit using the data obtained
from three experiments (employing two different blood donors) are shown in (D).around 600 Å2 of the solvent-accessible surface [48,
49]. It is possible that the inhibitors we describe bind
at or near this site and effectively block ligand binding,
although it is difficult to envisage how sufficient binding
energy could be generated in such a shallow pocket.
We therefore favor the view that binding follows a more
complex mechanism, such as the adaptive ligand bind-
ing seen with a nonpeptidyl small molecule antagonist
of IL-2 [50]. This issue will be resolved very easily in
planned mutational analyses and/or cocrystallization
studies.
CD80 contains two tandemly arranged immunoglob-
ulin (Ig)-like domains with the active site located in the
membrane distal V domain [49]. Ig-like domains consist
almost exclusively of β sheet structure and are by far
the most abundant protein domain observed in cell sur-
face molecules. Since there are relatively few examples
of small compounds known to interact with all β do-
mains, the compounds described herein are of signifi-
cant interest. One such example, SB 247464, binds the
N-terminal half of the extracellular domain of the GM-
CSF receptor [51], which consists of an Ig-like domain,
a cytokine receptor domain, and two fibronectin type
III domains, all of which are rich in β sheets. However,
SB 247464 does not compete with the native ligand and
instead acts as a cytokine mimetic, probably by induc-
ing receptor crosslinking [52]. It will be of considerable
interest to determine whether other leukocyte receptor/
ligand pairs, many of which represent excellent immu-
notherapeutic targets, are also amenable to blockade
with small compound inhibitors in the manner of CD80.
Among potentially therapeutic, CD80-related molecules
is the costimulatory molecule LICOS, which is impli-
cated in sustaining T cell activation and progression of
autoimmune disease [53].
To be clinically useful, small compound inhibitors ofcell surface protein-protein interactions need, by defini-
tion, to inhibit binding events at the junction between
interacting cells. Cell surface proteins are constrained
within two dimensions, and as such, binding is favored
between cognate receptor-ligand pairs when closely ap-
proximated. The inhibitory properties of the small com-
pounds described herein are consistent with the
multivalent nature of the CD28/CD80 interaction on
cells. For example, whereas compounds 2–6 described
herein showed potent inhibition of CD28/CD80 binding
in direct binding assays, their corresponding IC50 val-
ues in cellular assays are between two and three orders
of magnitude higher (Table 1). This reflects the avidity
enhancement of cell surface protein-protein interac-
tions not manifest when their soluble counterparts in-
teract in solution. Additional support for an avidity-
driven mechanism for CD28/CD80 binding is provided
by a recent study in which CD80-conjugated beads
were shown to bind CD28-transfected cells with an ap-
parent half-maximal binding value (Bmax/2) of 2–5 nM
[43]. This is approximately three orders of magnitude
lower than the KD of the interacting monomers (4 M)
[54]. Compound efficacy in cellular assays will also be
influenced by other, possibly more favorable factors,
however, such as the threshold below which there are
insufficient numbers of CD28/CD80 interactions to ef-
fect appropriate cellular responses. Significantly, it has
been shown in the NOD mouse model of autoimmune
diabetes that as little as a 50% reduction in the level of
endogenous CD80 cell surface expression due to gene-
dosage effects has a significant impact on the course
of disease [55].
Previously, Erbe et al. described CD80-specific com-
pounds that exhibited 4–17 nM potency in direct bind-
ing assays, but these compounds were unable to inhibit
adhesion between CD28- and CD80-transfected CHO
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Htion at 50 M) in a CD28-PI3-kinase association assay
((using Jurkat cells and CD80-transfected CHO cells)
B
[40]. For comparison, we synthesized compound 6q r
[40] and showed that it had an EC50 value of 177 nM in d
qour TR-FRET assay, compared with an IC50 of 4nM in
ethe original ELISA assay [41]. This discrepancy alone
mmay explain the relative lack of potency of compound
a6q in cellular assays. However, the level of CD80 sur-
C
face expression on transfected CHO cells may also be p
significant. Based on previous studies [56] and our own (
cobservations (data not shown), we noted relatively high
gcell surface expression of CD80 on transfected fibro-
bblasts. By comparison, the Raji cells used for the as-
Dsays herein express lower levels of CD80 and coex-
r
press CD86 (Figure 5A, inset). Thus, Raji cells more c
faithfully represent the CD80+/CD86+ phenotype of an
activated APC [10, 12, 14] and are therefore a more T
Tphysiologically relevant source of costimulation than
ftransfected fibroblasts. In terms of the responder cells,
sit is significant that primary CD4+ T cells proved sus-
bceptible to inhibition with the CD80 compounds at sub-
t
micromolar doses (Figure 6D), since results obtained p
with primary cells are clearly more likely to predict in vivo m
fefficacy.
b
mSignificance p
r
Targeting T cell costimulation remains one of the more 4
Vpromising avenues for modulating undesired immune
tresponses in autoimmune disease and transplanta-
stion. The CD80 costimulatory pathway is thoroughly
5
validated as a therapeutic target for the amelioration f
of disease in a variety of indications, including multiple o
sclerosis, rheumatoid arthritis, and graft rejection. The t
gmost effective currently available biologic therapies
gsuffer from the coincident problems of administration
and dosing, leading to high treatment costs. The CD80-
Sspecific small compound antagonists described herein
A
offer a realistic starting point for the development of H
alternative, nonprotein-based orally available thera- r
pies for autoimmune disease. Protein-protein interac- a
stions, such as those involving CD80 and CD28, are
ogenerally held to be problematic as targets for small,
wdrug-like compounds. Our results suggest that pro-
fteins involved in these interactions, in particular, q
those comprised of -rich domains that dominate the w
cell surface, may also be accessible as therapeutic u
stargets using small molecules.
j
fExperimental Procedures
FChemical Synthesis
CSynthesis methods for compounds 1 and 2 have been previously
bdescribed in patents WO03004495 [42] and WO2004048378 [57],
wrespectively. Compounds 3–6 can be readily prepared according
Mto published methods in patent WO2004081011 [58]. In brief, the
b4-chloro-cinnoline-3-carboxylic acid methyl ester and 4-hydrazino-
abenzoic acid are condensed together to form 4-(3-oxo-1,3-dihy-
4dro-pyrazolocinnolin-2-yl)-benzoic acid. This product can then be
readily converted to the acid chloride with oxalyl chloride in di-
chloromethane. Reaction with the appropriate amine affords the C
Cdesired product. The relevant patents describing synthesis methods
[42, 57, 58] may be accessed free of charge at http://ep.espacenet. k
tcom.ecombinant Protein Production
uman soluble CD80 (sCD80) and human and mouse soluble CD28
sCD28) proteins were available as Fab and Fc fusions from Active
iotech AB (Lund, Sweden) [43]. Human, rhesus monkey, mouse,
at, and canine CD80 constructs with C-terminal BirA-tags were
erived by PCR using oligonucleotide primers to amplify cDNA se-
uences from either commercially available libraries or cDNA gen-
rated by the reverse-transcriptase method using peripheral blood
RNA or assembled using overlapping synthetic oligonucleotides
ccording to published sequences. cDNAs encoding rat and canine
D28 were made in similar fashion and expressed as Fc-fusion
roteins. All constructs were subcloned into the pEE14.4 vector
Lonza Biologics, Slough, UK) for expression in CHO cells, and re-
ombinant proteins were purified by lentil lectin affinity chromato-
raphy as described previously [59]. Soluble CD80 proteins were
iotinylated using the BirA enzyme in the presence of 1.5 mM
-biotin, 7.6 mM MgCl2, and 5 mM ATP and then separated from
eaction products by size exclusion chromatography. Details of the
onstruct design and characterization will be described elsewhere.
R-FRET Assay
he interaction between sCD80-Fab fusion protein and sCD28-Fc
usion protein in solution was detected by anti-Fc and anti-kappa
econdary antibodies and by a europium-conjugated tertiary anti-
ody and streptavidin-allophycocyanin conjugate. On formation of
he complex, europium and allophycocyanin are brought into close
roximity and a signal is generated. Nonspecific interaction was
easured by substituting a mouse immunoglobulin Fab fragment
or the sCD80-Fab fusion protein. The assay was carried out in
lack 384-well plates in a final volume of 30 l in 150 mM NaCl, 50
M Tris (pH 7.8) (HCl), 0.1% (w/v) bovine serum albumin. Com-
ounds were added to the above reagents in a concentration series
anging from 100 M to 1.7 nM, and the reaction was incubated for
hr at room temperature. Dual measurements were made using a
ictor 1420 Multilabel Counter (Wallac). First measurement, excita-
ion 340 nm, emission 665 nM, delay 50 s, window time 200 s;
econd measurement, excitation 340 nm, emission 615 nm, delay
0 s, window time 200 s. Counts were automatically corrected
or fluorescence crossover, quenching, and background. Inhibition
f the CD80/CD28 interaction was detected by diminution of emit-
ed fluorescence at 665 nm. The assay was robust and capable of
enerating reliable SAR, with a signal to background ratio of 2.5:1,
iving an average Z factor per 384-well plate of 0.75.
PR Assays
ll assays were performed on Biacore S51 (Biacore AB, St Albans,
ertforshire, UK) at an analysis temperature of 25°C. Biotin-labeled
ecombinant proteins were immobilized by high-affinity capture to
series S sensor chip (CM5) surface that was first coated with
treptavidin. Immobilization levels were 3000–3500 RU using CD80
n spot 2 and CD86 as a negative control on spot 1. Running buffer
as 10 mM HEPES (pH 7.4), 150 mM NaCl containing 0.005% sur-
actant P-20 and supplemented with 5% (v/v) DMSO where re-
uired. Compound characterization assays (Biacore S51 software
izard) were run using a flow rate of 30 l/min with three start-
p cycles and eight-point solvent correction cycle run after every
econd dilution series. Sample cycles consisted of a 60–200 s in-
ection phase followed by a 400–1000 s dissociation phase and a
inal wash with 50% DMSO.
low Cytometry
ell surface expression of costimulatory receptors was analyzed
y fluorescence-activated cell sorter (FACS) analysis. Cells (2 × 105)
ere incubated with 100 l appropriately diluted CD80 (clone
EM-233, Serotec) or CD86 (clone BU63, Serotec) mAb which had
een directly conjugated with FITC. Cells were washed and then
nalyzed using a FACSVantage (BD Biosciences) equipped with a
88 nM laser.
ellular Assays
ompounds were prescreened at a concentration of 30 M on Jur-
at and Raji cells (ATCC, LGC, Teddington, Middlesex, UK) using
he Alamar Blue redox indicator dye assay to exclude toxic candi-
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1657dates prior to screening in functional assays [60]. A costimulation-
dependent IL-2 release assay was developed by dispensing human
Raji (Burkitt’s lymphoma) cells at a density of 2 × 105 cells per well
in RPMI-1640 medium supplemented with 10% fetal calf serum,
1% penicillin/streptomycin, 1% glutamine (RPMI medium) in a 96-
well round bottom microtitre plate. Compounds (dissolved in 100%
DMSO) were added to make up a volume of 200 l/well at the de-
sired final concentration. In control experiments, antagonist mAbs
to CD80 (clone L307.4, BD-Pharmingen) and CD86 (clone IT2.2, BD
Pharmingen) were added in place of compounds. After 20 min pre-
incubation of Raji cells and blocking agent at 37°C, Jurkat T cells
were added to a final density of 2 × 105 cells per well. Monoclonal
antibody to CD3 (OKT3, ATCC) was added to the cultures at a final
concentration of 0.06 g/ml. Cells were cultured at 37°C for 5 hr,
after which the plates were centrifuged and the supernatants har-
vested for IL-2 ELISA assay (DIACLONE Research, Besancon,
France) according to the manufacturer’s instructions. Maximum IL-2
levels at 5 hr post-stimulation usually ranged from 0.3 ng/ml–1.5 ng/
ml, and supernatants were appropriately diluted (usually 1:3) prior
to assay. An anti-CD3/anti-CD28 control assay was developed by
adding the antibody CD28.2 (BD-Pharmingen, San Jose, CA) to the
Jurkat assay at a final concentration of 0.3 g/ml. After 5 hr, super-
natants were harvested and assayed for IL-2 as described above.
Primary human CD4+ T cells were purified from buffy coats (Na-
tional Blood Transfusion Service, Bristol, UK) using a CD4 T cell
negative isolation kit (Miltenyi, Gladbach, Germany). CD4+ T cells
were cocultured with Raji cells as described for the Jurkat assay,
except that the CD3 mAb UCHT-1 (BD-Biosciences) was used at
0.125 g/ml. Supernatants were harvested and analyzed for IL-2,
IFNγ, and TNFα by ELISA (DIACLONE).
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